Cognition Therapeutics publishes research on zervimesine in dry AMD

Cognition Therapeutics (CGTX) announced the publication of a manuscript reviewing recent work supporting the potential of zervimesine, a small molecule drug candidate to treat dry age-related macular degeneration. The Journal of Nature Scientific Reports has published the paper online. Several separate studies were conducted and are reported in this manuscript: an analysis of cerebrospinal fluid collected from participants of two Alzheimer’s disease clinical trials to identify the impact of zervimesine treatment on disease-relevant proteins; a separate analysis of these CSF samples to identify pathways associated with dry AMD that were altered by treatment with zervimesine; an in vitro study conducted in collaboration with researchers at the University of Southampton, UK to investigate zervimesine’s ability to rescue important cellular processes in a cell model of dry AMD. Mary Hamby, Ph.D., Cognition Therapeutic’s VP of research explained, “We analyzed CSF samples from studies of zervimesine in adults with mild-to-moderate Alzheimer’s disease. From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular degeneration. These findings support the potential of zervimesine to impact pathways impaired in retinal diseases.”